Effects of mesalazine combined with Bifidobacterium tetravaccine capsules on ulcerative colitis

Abstract

Objective To observe the effects of mesalazine combined with Bifidobacterium tetravaccine capsules on ulcerative colitis (UC). Methods A total of 124 patients with UC treated in the Fifth People’s Hospital of Datong from May 2017 to April 2018 were selected as research objects, and they were divided into two groups by the random number table method, with 62 cases in each group. The control group was treated with mesalazine, and the observation group was treated with Bifidobacterium tetravaccine capsules and mesalazine. Clinical efficacy, inflammatory immune response and adverse reactions of the two groups were observed before and after treatment. Results After treatment, the total efficiency of the observation group was 93.55% (58/62), higher the 79.03% (49/62) of the control group, and the difference was statistically significant (P 0.05). After treatment, the levels of IgA, IgG and TNF-a in the observation group were (1.32±0.58)g/L, (8.16±0.54)g/L, (271.59±32.34)ng/L, respectively, lower than the (1.75±0.34)g/L, (10.59±0.47)g/L, (346.65±40.08)ng/L in the control group (P 0.05). Conclusions Methalazine combined with Bifidobacterium tetravaccine capsules in the treatment of UC patients is more helpful to suppress inflammatory response, improve immune function, and it is safe and effective. Key words: Ulcerative colitis; Mesalazine; Bifidobacterium tetravaccine capsules; Inflammatory immune response